The addition of the patient-facing family history platform will expand and enhance Invitae's existing genome management support services, the company said.
The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.
Dubbing itself a "telegenomics company," San Francisco startup Genome Medical announced the launch this week of its genetic consultation services offering.
The telegenomics startup will use the proceeds to support the rollout of its genetic consultation services. A pilot version of the services was launched last fall.
The partners will combine the analysis of high-risk inherited genes and several hundred SNPs into a single NGS test for inherited cancer risk.
Invitae said that it accessioned more than 26,000 samples for testing during the quarter, a 166 percent increase over Q1 2016.
One paper involving experts from Myriad Genetics and another from Invitae added fresh data to a contentious debate over the use of public variant databases.
Through this Alnylam-funded program, Invitae will perform free testing for US patients suspected to have hereditary ATTR amyloidosis or a family history of it.
The GenomeWeb Index rose nearly 5 percent in February, on par with the Dow and slightly outperforming the Nasdaq.
Invitae reported $9.2 million in fourth quarter revenues compared to $3.2 million in the year-ago period, beating the consensus Wall Street estimate of $8.8 million.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.